<DOC>
	<DOCNO>NCT00001993</DOCNO>
	<brief_summary>The primary objective study determine preliminary efficacy tolerability combine select dose SC-48334 low-dose AZT treatment symptomatic HIV+ patient 200 500 CD4+ cells/mm3 . The secondary objective determine pharmacokinetics bioavailability SC-48334 AZT , administer together , symptomatic HIV+ patient 200 - 500 CD4+ cells/mm3 .</brief_summary>
	<brief_title>Initial Phase II Efficacy Safety Study SC-48334 Administered Combination With Low-Dose Zidovudine ( AZT ) Symptomatic HIV-1 Infected Patients With = &gt; 200 = &lt; 500 CD4+ Cells/mm3</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Medications prophylaxis opportunistic infection , : Aerosolized pentamidine . Trimethoprim/sulfamethoxazole . Nystatin . Clotrimazole . Antimycobacterial agent . Ganciclovir . Topical acyclovir . Patients must follow : CD4+ cell count = &gt; 200 &lt; 500 /cell mm3 . For purpose inclusion absolute CD4+ cell count must = &gt; 200 &lt; 500 cells/mm3 first sample = &gt; 190 &lt; 510 cells/mm3 second sample . Have least one following : Oral candidiasis . Herpes zoster last 3 year . Oral hairy leukoplakia past three year . Chronic ( &gt; 30 day period ) , recurrent seborrheic dermatitis , topical , pruritic folliculitis ( itchy bump ) . Unintentional weight loss excess 10 pound 10 percent usual body weight . Chronic fatigue present past 6 month , interfere normal activity least 1 2 time per week . HIV antibody positive determine federally license Enzymelinked Immunosorbent Assay ( ELISA ) . Documented , write informed consent must obtain prior admission study . Prior Medication : Allowed 12 week prior study entry : Zidovudine ( AZT ) . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Malignancies , exception basal cell carcinoma . Significant organ dysfunction . Concurrent Medication : Excluded : All antiretroviral drug exception Zidovudine . Cancer chemotherapeutic agent . Antimetabolites alkylating agent . All investigational nonFDA approve drug . Patients follow exclude : Clinically significant diarrhea ( &gt; 3 liquid stool per day &gt; 7 day ) without definable cause , within 6 month prior enrollment ) . Diarrhea , , know , nonHIV relate cause occur within one month prior enrollment . Meets CDC criterion AIDS classification . Chronic fever ( &gt; 38.5 C persist 14 consecutive day , 15 day 30day interval prior study entry ) . Malignancies , exception basal cell carcinoma . Significant organ dysfunction . Known hypersensitivity SC48334 related compound . History lactose intolerance . Prior Medication : Excluded within 30 day study entry : Any investigational medication . Treatment drug ( Zidovudine ) antiHIV activity . Excluded &gt; 12 week prior study entry : Zidovudine ( AZT ) . Excluded within 90 day study entry : Ribavirin . Excluded within 6 month study entry : Cancer chemotherapy . Excluded : Treatment SC48334 . Prior Treatment : Excluded within 30 day study entry : Electron beam radiation . Excluded within 6 month prior study entry : Required HIVrelated blood transfusion . Whole body radiation . Current use illicit substance ; current abuse alcohol , use would limit compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1992</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
</DOC>